BD Diagnostics, a segment of Becton, Dickinson and Co., has announced it has received FDA clearance for nasopharyngeal wash, aspirate and swab in transport media specimens on the BD Veritor system for detection of flu A+B, according to a news release.
This new laboratory kit is configured for testing liquid specimens obtained via nasopharyngeal wash, aspirate or swab in transport media, according to the company. The system eliminates the interpretation of visually read assays.
"Visually read rapid flu tests have shown variable performance results and are prone to errors when interpreting results," said Tom Polen, president, BD Diagnostics – Diagnostic Systems, in the release. "The BD Veritor system provides an advanced rapid diagnostic test for influenza A+B by offering accuracy, consistency, and convenience along with an objective read that laboratorians can trust."
The clinical lab version joins the previously FDA-cleared BD Veritor system for rapid detection of flu A+B.
BD Diagnostics is headquartered in Sparks, Md.
Related Articles on FDA Clearances:
InnerOptic Receives FDA Clearance for Needle-Based Interventions 'GPS'
Cardinal Health Receives Additional FDA Clearances for Durablue Sterilization Wrap
Aptus Endosystems Receives FDA Clearance for Aortic Securement System